Why read
AI can make a life workflow look effortless in a demonstration. This note explains how to turn that promise into a bounded buying question with measurable outcomes, accountable review, and evidence a buyer can challenge.
The short answer: Start with the job, not the model. Define the outcome, identify what can and cannot be automated, compare public evidence and limitations, then test integration, governance, and market readiness in a controlled pilot.
For: Enterprise life leaders, operators, risk owners, and technology teams.
Start with the decision
A useful life AI comparison starts with a decision a real team needs to make. It might reduce a queue, improve a forecast, find a risk, support a customer, or help a specialist work through evidence. A page that only repeats a vendor category does not tell the buyer what success would look like.
Write the intended user, input, output, workflow boundary, accountable owner, and measurable baseline before comparing products.
Separate useful assistance from delegated authority
The strongest early use cases support people with retrieval, classification, summarisation, prediction, or workflow routing. That does not mean the system should make the final customer, financial, safety, editorial, or operational decision. Human review needs an actual role, time, evidence, and escalation path.
The guidance from FDA artificial intelligence for drug development and FDA and EMA good AI practice principles shows why accountability, documentation, monitoring, and risk management still matter when a third-party system performs the work.
Evidence: FDA artificial intelligence for drug development, FDA and EMA good AI practice principles
What a serious buyer should ask for
Ask for the exact intended use, evaluation data, known failure modes, human oversight, access controls, retention, incident process, model and feature change policy, integration details, customer references, and exit plan. Ask which claims are independently evidenced and which are only vendor statements.
A pilot should compare the system with the current process, not with a blank page. Measure quality, time, exception rate, user behaviour, customer impact, and control effectiveness.
Evidence: FDA and EMA good AI practice principles
What this site does and does not do
This site organises public product and policy sources about life AI into a transparent catalogue. It does not certify a supplier, give professional advice, prove local compliance, or replace procurement, legal, security, safety, or domain review.
Products remain unscored until product-specific evidence is reviewed for the intended use and market.
Evidence: FDA artificial intelligence for drug development, FDA and EMA good AI practice principles
What to verify next
- Choose one bounded workflow and define its baseline.
- Request the vendor evidence and assurance pack.
- Run a controlled pilot with business, domain, security, privacy, and procurement owners.
What this does not prove
- Public evidence changes and may not describe a buyer's exact contract, configuration, data, or market.
- Scores are evidence-quality indicators, not product quality, certification, financial advice, or implementation approval.
Claims to check
- fact: FDA artificial intelligence for drug development identifies material governance, accountability, and risk-management responsibilities for AI use in the industry. (FDA artificial intelligence for drug development)
- analysis: A vendor product page can describe intended use and features, but it does not by itself prove independent outcomes or local readiness. (FDA and EMA good AI practice principles)
- inference: The practical buying insight is that evidence, workflow ownership, integration, and monitoring should be tested together. (FDA artificial intelligence for drug development, FDA and EMA good AI practice principles)
This note is informational research, not professional advice. Product and policy facts should be checked against the linked sources and current market conditions.